ArticleFrontiers in pediatrics2026
Neonatal-onset cblC-type methylmalonic acidemia combined with homocysteinemia: case report.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical diagnostic features, screening and definitive diagnostic methods of neonatal-onset cblC type methylmalonic acidemia (MMA) combined with homocysteinemia, so as to provide a reference for early clinical identification and diagnosis of this disease. Methods: The clinical data of 1 neonate with neonatal-onset cblC type MMA combined with homocysteinemia admitted to our hospital were retrospectively analyzed. Routine laboratory tests, blood tandem mass spectrometry, serum homocysteine test, urinary organic acid analysis, cranial MRI and genetic testing were performed on the neonate. Combined with relevant literature, the clinical features, diagnostic strategies, treatment and prognosis of the disease were reviewed and summarized. Results: The patient was a 20-day-old male neonate, presenting with persistent feeding difficulty and weak response after birth as the main manifestations, accompanied by hypotonia and diminished primitive reflexes, without typical critical signs. Laboratory examinations showed significantly elevated serum homocysteine; blood tandem mass spectrometry revealed increased propionylcarnitine, elevated C3/C2 ratio and decreased methionine; urinary organic acids showed increased methylmalonic acid and methylcitric acid. Cranial MRI showed hyperintensity in the bilateral globus pallidus on T1WI. Genetic testing identified two heterozygous pathogenic variants, c.567dupT and c.609G>A, in the Conclusion: Neonatal-onset cblC type MMA combined with homocysteinemia has insidious and non-specific clinical manifestations, which are easily confused with other neonatal diseases, leading to missed diagnosis and misdiagnosis. For neonates with unexplained feeding difficulty, poor mental response and abnormal muscle tone, timely metabolic screening including blood tandem mass spectrometry, urinary organic acid analysis and serum homocysteine test should be conducted. Genetic testing is the gold standard for the definitive diagnosis and classification of this disease, and can also provide a basis for genetic counseling and prenatal diagnosis. The implementation of neonatal screening for inherited metabolic diseases and the establishment of a multidisciplinary collaborative diagnosis and treatment model are the keys to achieving early diagnosis and treatment of this disease and improving the prognosis of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.